Table 3 Significantly regulated transcripts of metabolic pathways in liver tissue between two ontogenetic stages within one dietary group (Ingenuity Pathway Analysis)

94 dpc vs. 1 dpn

AP

AMPK signaling

up

6.96*E-3

8

AKT2, INSR, PIK3C2A, PIK3R1, PPM1B, PRKAA1, PRKACB, RAC1

AP

Mitotic roles of Polo- like kinase

down

3.25*E-4

7

CCNB1, CCNB2, CDC25B, CHEK2, KIF11, PLK4, PTTG1

AP

Pyrimidine metabolism

down

2.52*E-3

10

CAD, DCTD, DKC1, POLQ, POLR3E, POLR3K, RFC5, RRM1, TYMS, UCK2

AP

G2/M DNA damage checkpoint regulation

down

2.04*E-4

6

CCNB1, CCNB2, CDC25B, CHEK2, UBC, YWHAE

LP

Purine metabolism

up

9.20*E-3

12

DDX39, PNPT1, POLA2, POLE2, POLR1B, POLR1C, POLR2I, RFC3, RRM2, RRM2B, RUVBL1, RUVBL2

LP

Pyrimidine metabolism

up

6.15*E-7

14

CTPS, PNPT1, POLA2, POLE2, POLR1B, POLR1C, POLR2I, PUS1, RFC3, RRM2, RRM2B, TXNRD1, TYMS, UCK2

LP

Mitotic roles of Polo- like kinase

up

7.55*E-5

7

ANAPC4, CDC27, CDK1, ESPL1, FZR1, PPP2R1B, PTTG1

LP

G2/M DNA damage checkpoint regulation

up

3.09*E-2

3

CDK1, CHEK1, YWHAZ

LP

Wnt signaling

down

4.02*E-2

9

AKT3, FZD5, MMP7, NLK, SOX4, TCF3, TCF4, TCF7L2, WNT5A

1 dpn vs. 28 dpn

AP

AMPK signaling

up

4.26*E-3

8

AK1, CPT1A, EIF4EBP1, HMGCR, MAPK14, NOS3, PRKAA2, PRKAB2

AP

mTOR signaling

up

1.89*E-2

7

EIF3F, EIF3G, EIF4EBP1, FNBP1, GNB1L, PRKAA2, PRKAB2

AP

Val, Leu, Ile degradation

down

6.40*E-3

6

ACAD8, ACADL, ACADSB, BCAT1, DBT, MCCC2

LP

Val, Leu, Ile degradation

up

7.12*E-8

11

ACADSB, ACAT1, ACAT2, ALDH1A1, AUH, BCKDHB, GCDH, HMGCL, HMGCS1, MCCC2, MCEE

LP

Fatty acid metabolism

up

3.23*E-3

8

ACADSB, ACAT1, ACAT2, ALDH1A1, AUH, CYP51A1, GCDH, PECI

LP

Synthesis and degradation of ketone bodies

up

1.76*E-6

5

ACAT1, ACAT2, BDH2, HMGCL, HMGCS1

LP

Biosynthesis of steroids

up

3.27*E-4

5

CYP24A1, FDPS, HMGCR, IDI1, SC5DL

LP

Glucocorticoid receptor signaling

up

3.57*E-3

12

CDKN1C, CXCL3, IL10, MAP3K1, NCOA2, NFKBIB, NR3C1, POLR2B, PRKACB, RRAS2, SLPI, SMARCA4

LP

G1/S checkpoint regulation

down

2.22*E-2

4

CCNE1, CDC25A, CDKN1A, E2F3

28 dpn vs. 188 dpn

AP

AMPK signaling

up

1.50*E-3

10

INSR, MAPK12, PPAT, PPM1A, PPP2CA, PPP2R3A, PRKAA2, SMARCA2, SRC, STK11

AP

Fatty acid metabolism

up

1.28*E-2

8

ACADSB, ALDH1A1, CYP1B1, CYP2D6, CYP3A4, CYP4A11, CYP4B1, PECI

AP

Mitotic roles of Polo- like kinase

down

8.33*E-3

7

ANAPC5, CDK1, PLK1, PLK2, PPP2R1B, SLK, WEE1

AP

VEGF signaling

down

7.3*E-3

9

AKT3, BCL2, KDR, NOS3, PRKCB, RAC2, RRAS, VCL, VEGFC

LP

Val, Leu, Ile degradation

up

1.07*E-2

7

ACAA1, ACAT1, ALDH1B1, AUH, ECH1, IVD, IWS1

LP

Fatty acid elongation in mitochondria

up

2.05*E-2

3

ACAA1, AUH, ECH1

LP

mTOR signaling

up

2.65*E-2

10

AKT3, DDIT4, EIF4B, EIF4G3, PPP2R1B, PRKAB2, PRKAG1, PRKAG2, TSC1, VEGFA

LP

Actin cytoskeleton signaling

down

7.99*E-5

24

ACTB, ACTR2, ARPC4, ARPC1A, CD14, CFL1, F2R, FGD1, LBP, MAP2K1,

MYH9, NCKAP1, PAK2, PIK3C3, PIK3C2A, PIK3R4, PIKFYVE, PPP1R12A, RDX, ROCK1, ROCK2, TMSB4X, TMSL3, WASF1

LP

RhoA signaling

dow

5.05*E-3n

12

ACTB, ACTR2, ARHGAP1, ARPC4, ARPC1A, CFL1, PIKFYVE, PPP1R12A, RDX, ROCK1, ROCK2, WASF1

LP

Rac signaling

down

4.34*E-3

12

ACTR2, ARPC4, ARPC1A, CFL1, MAP2K1, NCKAP1, PAK2, PIK3C3, PIK3C2A, PIK3R4, PIKFYVE, WASF1

LP

Complement system

down

2.17*E-2

5

C2, C7, C9, CFB, MBL2